Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity.

Primary tabs

field_vote: 
Average: 7 (1 vote)
Therapeutic intervention: 
Therapeutic Substance(s): 
Disease(s): 

Ann Oncol. 2004 Oct;15(10):1543-50.

Comment in:
Ann Oncol. 2005 Apr;16(4):673.

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity.
 
Rozados VR, Sánchez AM, Gervasoni SI, Berra HH, Matar P, Graciela Scharovsky O.

Instituto
de Genética Experimental, Facultad de Ciencias Médicas, Universidad
Nacional de Rosario, Santa Fe 3100 (2000) Rosario, Argentina.
BACKGROUND:
Our aim was to investigate the clinical efficacy and toxicity of
metronomic administration of low-dose cyclophosphamide (Cy) in lymphoma
and sarcoma rat tumour models.
METHODS: Adult inbred rats were
challenged with lymphoma TACB and sarcoma E100 s.c. on day 0. Animals
were divided into two groups: group I, control, injected with saline
three times a week; and group II, treated with Cy 10 mg/kg three times
a week, from day 10 until the tumour was non-palpable, or 5 mg/kg three
times a week from day 7. Tumours were measured and animals were weighed
twice weekly. Periodic blood samples were taken for determination of
urea, creatinine, serum glutamic-oxaloacetic transaminase, lactate
dehydrogenase and haematological parameters.
RESULTS: The
administration of low-dose Cy eradicated established rat lymphomas and
sarcomas; there was neither metastatic growth nor recurrence at primary
sites for 100% of the lymphomas and 83% of the sarcomas. In addition,
the treatment did not cause weight loss, and was devoid of
haematological, cardiac, hepatic and renal toxicity.
CONCLUSIONS:
Metronomic administration of Cy at low doses on a thrice weekly
schedule to already grown rat lymphomas and sarcomas demonstrated
itself to be a successful antitumour therapy that did not cause weight
loss and was devoid of haematological, cardiac, hepatic and renal
toxicity.